4 February 2010

Avita awarded $450K from US armed forces to speed approval of spray-on skin

Science|Business

Funding

Avita Medical Ltd, has been awarded a further $450,000 from the US Armed Forces Institute of Regenerative Medicine, to expedite approval of the company’s ReCell autologous spray-on skin in the US market.

The award is in addition to the $1.45 million granted to Avita by the institute in May 2009.

The additional funding follows recognition of the value of ReCell in the Department of Defense’s regenerative medicine programme, which was set up in April 2008 to apply regenerative techniques to the treatment of wounded soldiers.

Avita Medical CEO William Dolphin said the original grant and the additional funding is a substantial endorsement. “The Department of Defense has recognized the major benefits which ReCell provides to patients and...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.